Navigation Links
Corgenix Reports Third Quarter Fiscal 2008 Financial Results
Date:5/15/2008

Total revenues for the quarter decrease approximately 3% vs. prior year

DENVER, May 15 /PRNewswire-FirstCall/ -- Corgenix Medical Corporation (OTC Bulletin Board: CONX), a worldwide developer and marketer of diagnostic test kits, today filed its third quarter Form 10-QSB and reported financial results. The report disclosed that the company's sales and operating results have advanced during the quarter and nine months ended March 31, 2008, and further confirmed that the initiatives the company put in place several months earlier are continuing to prove effective. Some of the results highlighted by the report are as follows:

-- Total revenues for the quarter decreased $61,166 or 3.1% vs. the prior

year's comparable quarter.

-- Revenues, excluding contract manufacturing, increased $186,686 or 10.6%

vs. the prior year's comparable quarter.

-- Total operating expenses decreased $30,009 or 2.4% vs. the prior year's

comparable quarter.

-- Operating loss for the quarter was $62,912 vs. an operating loss of

$37,423 in the prior year's comparable quarter.

-- Net loss for the quarter was $352,102 vs. $329,370 in the prior year's

comparable quarter.

"While much was accomplished in the quarter, including product sales growth and reduction in operating expenses, the overall financial results in the third quarter were less than we had expected, reflecting to some extent, the timing of our sales orders, but to a greater extent, softer sales in the contract manufacturing aspect of our business, which was a direct result of the new business strategy of our largest contract manufacturing customer," said Douglass Simpson, President and CEO of Corgenix. "Excluding contract manufacturing, our sales increased 10.6% over the same period in the prior year. It's important to recognize that Corgenix is still growing well ahead of industry averages -- our sales are up almost 20% for the nine m
'/>"/>

SOURCE Corgenix Medical Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Corgenix to Exhibit AspirinWorks(R) Test at 2008 ACOFP Meeting in Denver
2. Tiens Biotech Group (USA) Reports First Quarter Results
3. Cardiogenesis Reports First Quarter 2008 Results
4. STEN Corp. Reports 2008 Second-Quarter Revenue of $4.3 Million and Improved Results From Operations
5. Alseres Pharmaceuticals, Inc. Reports First Quarter 2008 Operational and Financial Results
6. The Female Health Company Reports 267% Increase in Second Quarter Earnings
7. NicOx Reports First Quarter 2008 Financial Results
8. Hill-Rom Reports Second Quarter Revenue Growth of 12.0 Percent to $375.2 Million and Adjusted Earnings Per Fully Diluted Share from Continuing Operations of $0.26, Unchanged from the Prior Year
9. IRIDEX Reports First Quarter 2008 Financial Results
10. Cardiome Reports First Quarter Results
11. MiddleBrook Pharmaceuticals Reports First Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... May 22, 2013 Nearly 50,000 veterans ... (BVA) in fiscal year 2012, with even more—54,033—expected by ... longer for a decision as the agency reports reduced ... provides veterans disability appeal services. The BVA ... Affairs. , Although the BVA received 49,611 cases in ...
(Date:5/22/2013)... A new study shows there is a gender ... American young children one that does not appear ... United States, girls had higher levels of self-regulation than ... their behavior and impulses, follow directions, and persist on ... and college completion, in past studies by Oregon State ...
(Date:5/22/2013)... 22, 2013 Successful Therapy for ... O’Laughlin Psychotherapy in the Silver Lake community of ... ages as progression to existing Parents and Couples ... into parenting therapy has always been suggested, but ... Psychotherapy now specializes in all aspects of ...
(Date:5/22/2013)... (PRWEB) May 22, 2013 Diversity Focus ... Handicap This! The performance promotes awareness that physical ... The Handicap This! performance will be held Friday, June ... School auditorium. Tickets for Handicap This! can be ... helps audiences measure the level to which their mind ...
(Date:5/22/2013)... (PRWEB) May 22, 2013 Today, Zane ... Alabama Health Insurance Exchange . Zane Benefits, which provides ... benefits, is the leader in defined contribution plans ... to Zane Benefits’ website, beginning in 2014 as part ... for individuals and small businesses will become available through ...
Breaking Medicine News(10 mins):Health News:Veterans Disability Appeals See Fewer Decisions in FY2012, Reports Allsup 2Health News:'Boys will be boys' in US, but not in Asia 2Health News:'Boys will be boys' in US, but not in Asia 3Health News:Patricia O’Laughlin Psychotherapy of Los Angeles Now Seeing Adults, Teens and Young Children 2Health News:Handicap This! Comes to Marion, Iowa 2Health News:Zane Benefits Publishes New Information on Alabama Health Insurance Exchange 2Health News:Zane Benefits Publishes New Information on Alabama Health Insurance Exchange 3
... with $150K Donation to the University of Pittsburgh ... After losing a battle to Merkel Cell Carcinoma, an aggressive and deadly ... through a donation by the Al Copeland Foundation to the University ... Copeland Day on June 28, 2009. , , Al Copeland ...
... June 30 Biopure Corporation (Nasdaq: BPUR ) ... by letter dated June 24, 2009, that it is out of ... be delisted. The notice stated that the company no longer ... on the Nasdaq Capital Market. , , Nasdaq advised that ...
... reduced pain and restored mobility in tendinitis patients, study ... of people suffer from tendinitis of the rotator cuff, ... pain and restore mobility of the shoulder, Italian researchers ... tendinitis, which involves small calcium deposits within the tendons ...
... high percentage of women responded favorably to a bioidentical ... , MAPLE GROVE, Minn., June 30 Upsher-Smith ... to determine the response rates to three doses of ... 57th Annual Clinical Meeting of the American College of ...
... SOUTH SAN FRANCISCO, Calif., June 30 Hyperion Therapeutics, ... development of therapies that address critical unmet needs in ... has closed a $60 million Series C financing. New ... financing. Series A and B investors Highland Capital Partners, ...
... the most out of treatment during the summer months and beyond ... the arrival of summer means more time outdoors, with trips to ... more enjoyable than soaking up the sun and having fun with ... actually mean a worsening of symptoms and the need for extra ...
Cached Medicine News:Health News:Al Copeland Day Lives on Through Efforts To Cure Merkel Cell Carcinoma 2Health News:Al Copeland Day Lives on Through Efforts To Cure Merkel Cell Carcinoma 3Health News:Nonsurgical Treatment May Ease Rotator Cuff Injury 2Health News:New Data: Efficacy and Responder Analyses of Divigel(R) (estradiol gel) 0.1 percent for the Treatment of Menopause 2Health News:New Data: Efficacy and Responder Analyses of Divigel(R) (estradiol gel) 0.1 percent for the Treatment of Menopause 3Health News:New Data: Efficacy and Responder Analyses of Divigel(R) (estradiol gel) 0.1 percent for the Treatment of Menopause 4Health News:New Data: Efficacy and Responder Analyses of Divigel(R) (estradiol gel) 0.1 percent for the Treatment of Menopause 5Health News:Hyperion Therapeutics Raises $60 Million Series C 2Health News:Hyperion Therapeutics Raises $60 Million Series C 3Health News:Summertime Sun Exposure Can 'Burn' Acne Sufferers in More Ways than One 2Health News:Summertime Sun Exposure Can 'Burn' Acne Sufferers in More Ways than One 3
(Date:5/22/2013)... WORCESTER, Mass. and TORONTO ... www.generex.com ) (OTCBB: GNBT) today announced three presentations demonstrating ... developed by its wholly-owned subsidiary, Antigen Express, Inc. ( ... annual meeting of the American Society of Clinical Oncology ... from May 31 through June 4, 2013. ...
(Date:5/22/2013)... 2013  Grifols, a global healthcare company based in ... a study demonstrating that a higher dose of PROLASTIN ... of the alpha 1 protein in patients with ... considered within the normal range for healthy individuals. AAT ... levels of the alpha 1 proteinase inhibitor (A1PI) ...
(Date:5/22/2013)... LAKES, N.J. , May 22, 2013  BD ... a leading global medical technology company, announced today the ... is BD,s fifth Sustainability Report and it continues to ... "We believe the principles of shared ... and addressing healthcare challenges of societies — are fundamental ...
Breaking Medicine Technology:Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine 2Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine 3Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine 4Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency 2Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency 3Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency 4BD Issues 2012 Sustainability Report 2BD Issues 2012 Sustainability Report 3
... Accuray Incorporated (Nasdaq: ARAY ) ... announced acquisition of TomoTherapy Incorporated (Nasdaq: TOMO). The ... best-in-class technologies to fight cancer.  The combined company ... leading-edge treatment solutions that revolve around the patient. ...
... 13, 2011 Guidelines that reduce the use of mechanical ... of respiratory support can profoundly affect those children,s outcomes while ... researchers at Children,s Hospital Boston. The team, ... Medicine at Children,s Hospital Boston and the Neonatal Intensive Care ...
Cached Medicine Technology:Accuray Successfully Completes Acquisition of TomoTherapy 2Accuray Successfully Completes Acquisition of TomoTherapy 3Accuray Successfully Completes Acquisition of TomoTherapy 4Guidelines for Ventilator Use Help Premature Infants Breathe Easier 2Guidelines for Ventilator Use Help Premature Infants Breathe Easier 3
... STAARVISC II is a sterile nonpyrogenic, ... hyaluronate. STAARVISC II contains 12 mg/ml of ... daltons) sodium hyaluronate dissolved in physiological saline. ... the viscosity is 105,000 cps (105 Pa ...
The Sonic WAVE™is the first market-ready Alternative to Ultrasound...
... The Stat Profile pHOx series consists of six ... and critical care profiles. Measured tests include pH, ... %, hematocrit, hemoglobin, sodium, potassium, ionized calcium, chloride, ... less than one minute. Its space saving design ...
... compact Sleepscan Traveler provides the ultimate flexibility ... PSG data in the home, a patient ... sleep studies utilize the same powerful Sleepscan ... Sleepscan Traveler studies take full advantage of ...
Medicine Products: